ASND241115P175000
- 0.00
- 0.000.00%
Ascendis Pharma A/S Newsroom
While Shareholders of Ascendis Pharma (NASDAQ:ASND) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $191
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $174
Express News | Ascendis Pharma A/S : JP Morgan Cuts Target Price to $174 From $180
Septerna Proposes Terms for Upsized $175M IPO
Ascendis Pharma Is Maintained at Buy by TD Cowen
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160
European Equities Traded in the US as American Depositary Receipts Move Slightly Higher in Thursday Trading
Ascendis Pharma Ticks Higher Amid Report It Cancelled From Upcoming Conference
MBX Bio Drops Despite Bullish Views on Street
Septerna, Hypoparathyroidism Drug Developer, Files for $100M IPO
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug
Express News | Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Looking Into Ascendis Pharma's Recent Short Interest
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167